Please assess the completion status of the following clinical trial:

Trial Title: Ketamine Infusion for Adolescent Depression and Anxiety

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion:~MDD Cohort:~* Meet DSM-5 criteria for Major Depressive Disorder by structured interview (MINI-KID)~* CDRS-R score \>40.~* Failure to achieve remission with at least 1 adequate prior antidepressant trial (e.g. SSRI, SNRI, or TCA), meaning at least 8 weeks at therapeutic dosing, including at least 4 weeks of stable dosing.~Anxiety Cohort:~* Meet DSM-5 criteria for any of the following anxiety disorders: Social Anxiety Disorders, Generalized Anxiety Disorder, Separation Anxiety Disorder and/or Panic Disorder by structured interview (MINI-KID)~* ADIS Clinical Severity Rating ≥4 (moderately severe) for any of the 4 included anxiety disorders~* Failure to achieve remission with at least 1 adequate prior anxiolytic medication trial (e.g. SSRI, SNRI, or TCA), meaning at least 8 weeks at therapeutic dosing, including at least 4 weeks of stable dosing.~* Failure to achieve remission with previous CBT or subject declines current CBT therapy~Both cohorts:~* Stable psychiatric medications and doses for the month prior to enrollment. Subjects may continue to engage in any ongoing psychotherapy.~* Medically and neurologically healthy on the basis of physical examination and medical history.~* Parents able to provide written informed consent and adolescents must additionally provide assent.~Exclusion:~* Current inpatient hospitalization or active suicidal ideation requiring referral for inpatient hospitalization for safety.~* History of psychotic disorder or manic episode diagnosed by MINI-KID~* History of substance dependence diagnosis by MINI-KID (excluding tobacco) or positive urine toxicology.~* Pregnancy (urine pregnancy tests on the day of scans for menstruating girls).~* Inability to provide written informed consent according to the Yale Human Investigation Committee (HIC) guidelines in English.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Ketamine (Type: EXPERIMENTAL): Participants were randomly be assigned to receive a dose of 0.5 mg/kg of Ketamine (administered intravenously over 40 minutes with a maximum total dose allowed in this study will be 50mg).
- Midazolam (Type: EXPERIMENTAL): Participants were randomly assigned to receive a dose of 0.045mg/kg of Midazolam (administered Intravenously over 40 minutes with a the maximum total dose allowed in this study of 4.5mg),

Based on this trial design, predict the completion outcome and termination type (if applicable).